This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
McGill University researchers have developed and tested a new way to facilitate the creation of personalized genetic therapies for children with rare neurodevelopmental disorders. Currently, many children suffering from rare disorders are left without a realistic path to treatment, given that the underlying genetic changes may affect only a handful of patients. As such, there is a need for platforms that treat diagnosis as the starting point for therapeutic evaluation rather than the endpoint of a diagnostic journey.
The study presents a framework for making such therapies more accessible. Published in the American Journal of Human Genetics, it demonstrates a process to bridge the gap between genetic diagnosis and treatment by presenting a roadmap that connects diagnosis to the screening of individualized therapies. The paper is titled "Integrating clinical diagnostics with interventional genetics for neurodevelopmental disorders"
"This approach leverages a diagnosis to guide the design of a genetic-based therapy, with the aim of providing a more direct path to treatment," said lead author Julia Macintosh, a Ph.D. student in McGill's Department of Neurology and Neurosurgery.
What makes the approach different is that it creates a single workflow that takes patients from genetic diagnosis through treatment development and testing.
"This is a wonderful example of researchers at McGill University and CHU Sainte-Justine working together to support families in Quebec. We hope this model can also be useful to genetic diagnostic centers around the world," said senior author Carl Ernst, professor in McGill's Department of Psychiatry and head of the Interventional Genetics Unit at the Neuro.
Source link







